Publication

Video

Supplements and Featured Publications
Research Efforts Underway for RARA+ MDS and AML
Volume 1
Issue 1

Dr. Stein on the SELECT-AML-1 Trial in Newly Diagnosed AML

Author(s):

Eytan M. Stein, MD, discusses the phase 2 SELECT-AML-1 trial in patients with newly diagnosed acute myeloid leukemia.

Eytan M. Stein, MD, director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, discusses the phase 2 SELECT-AML-1 trial (NCT04905407) in patients with newly diagnosed acute myeloid leukemia (AML).

The phase 2 SELECT-AML-1 trial is examining the utilization of tamibarotene (Amnolake) plus venetoclax (Venclexta) and azacitidine (Vidaza) in patients with retinoic acid receptor alpha (RARA)–positive AML who are unlikely to tolerate standard intensive chemotherapy as a frontline treatment.

The first part of the trial will examine the safety of combining tamibarotene with venetoclax and azacitidine, followed by the second part of the study where patients will be randomized 1:1 to receive venetoclax and azacitidine with or without tamibarotene, Stein explains.

Notably, a subset of patients receiving venetoclax and azacitidine alone will be permitted to cross over to receive tamibarotene with venetoclax and azacitidine if they fail on treatment, Stein continues. The primary end points of SELECT-AML-1 will be complete remission rates and overall response rates, and exploratory end points included pharmacokinetics and additional safety, Stein concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.